Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Arsanis logo — Leading the fight against infectious diseases with advanced...

Arsanis

Leading the fight against infectious diseases with advanced monoclonal antibody therapies.

Founded 2010 11-50 employees Post Ipo Equity Total: $120.26M Biotechnology, Health Care +1

General Information

Company Name Arsanis
Founded Year 2010
Employees 11-50
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Post Ipo Equity
Social

Get notified when Arsanis moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Arsanis

Arsanis is a clinical-stage biopharmaceutical company founded in 2010 that focuses on developing monoclonal antibody (mAb) immunotherapies to combat serious infectious diseases. The company's lead clinical program, ASN100, targets Staphylococcus aureus infections and is currently in Phase 2 clinical trials. Arsanis has an extensive preclinical pipeline including mAbs against various bacterial and viral pathogens such as the respiratory syncytial virus. The company's extensive knowledge of infection pathogenesis, along with access to advanced mAb discovery techniques and platforms, positions Arsanis as a strong player in the biotechnology, health care, and life sciences industries. With its operations based in Waltham, Massachusetts, and its European research and preclinical development operations located in Vienna, Austria through Arsanis Biosciences GmbH, the company benefits from a geographically diverse presence. In December 2017, Arsanis received a $20.00M post-IPO equity investment, emphasizing investor confidence in the company's potential to advance the development of novel mAbs for infectious disease treatment. With its advancing pipeline of mAbs with multiple mechanisms of action and high potency, Arsanis holds promise in leading the fight against infectious diseases, making it an intriguing prospect for venture capital and investment.

Taxonomy: biopharmaceuticals, monoclonal antibodies, infectious diseases, clinical-stage, immunotherapies, mAb discovery, Staphylococcus aureus, Phase 2 clinical trial, preclinical pipeline, antibacterial therapies, viral pathogens, respiratory syncytial virus, Waltham, Massachusetts, Vienna, Austria, pathogenesis of infection

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 04 Dec 2017
Series D •••••• 7
Investor Investor Investor Investor Investor Investor Investor
26 Apr 2017
Grant •••••• 1
Investor
27 Feb 2017
Series C •••••• 1
Investor
27 Apr 2016
Debt Financing •••••• 1
Investor
12 Apr 2016

View All 9 Funding Rounds

Arsanis Alternatives & Competitors

Arsanis vs
GamaMabs Pharma
GamaMabs Pharma

Advancing the future of immuno-oncology with innovative monoclonal antibody treatments

Series B
7 employees
Biotechnology, Health Care
Arsanis vs
Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc. United States

Innovative pediatric immunotherapies for Real-life Possibilities

Post Ipo Equity
59 employees
Biotechnology, Health Care
Arsanis vs
Nimbus Therapeutics
Nimbus Therapeutics United States

We develop breakthrough medicines for patients through precision small molecule design.

Private Equity
99 employees
Biotechnology, Health Care

FAQ About Arsanis

Leading the fight against infectious diseases with advanced monoclonal antibody therapies.
Arsanis was founded in 2010.
Arsanis operates in the following industries: Biotechnology, Health Care, Life Sciences.
Arsanis has approximately 11-50 employees.
Arsanis has completed 9 funding rounds, raising a total of $120.26M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Arsanis include GamaMabs Pharma, Y-mAbs Therapeutics, Inc., Nimbus Therapeutics, Hemab Therapeutics, OSE Immunotherapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Arsanis and GamaMabs Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Arsanis and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy